UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review

Prostate cancer and prostatic diseases, 2020-12, Vol.23 (4), p.549-560

2020

Volltextzugriff (PDF)

Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression

International journal of molecular sciences, 2020-02, Vol.21 (4), p.1475

2020

Volltextzugriff (PDF)

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

European urology, 2022-03, Vol.81 (3), p.234-240

2022

Volltextzugriff (PDF)

Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study

Current oncology (Toronto), 2022-02, Vol.29 (2), p.945-955

2022

Volltextzugriff (PDF)

Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

Therapeutic Advances in Urology, 2016-10, Vol.8 (5), p.319-326

2016

Volltextzugriff (PDF)

Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study

Frontiers in oncology, 2021-05, Vol.11, p.671969-671969

2021

Volltextzugriff (PDF)

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Cancers, 2019-07, Vol.11 (7), p.980

2019

Volltextzugriff (PDF)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?

Journal of clinical medicine, 2020-03, Vol.9 (4), p.930

2020

Volltextzugriff (PDF)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

Cancers, 2019-02, Vol.11 (2), p.223

2019

Volltextzugriff (PDF)

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors

Therapeutic advances in medical oncology, 2016-09, Vol.8 (5), p.323-330

2016

Volltextzugriff (PDF)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Drugs in R&D, 2017-09, Vol.17 (3), p.461-467

2017

Volltextzugriff (PDF)

343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A209-A210

2020

Volltextzugriff (PDF)

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Cancer treatment and research communications, 2020, Vol.22, p.100161-100161, Article 100161

2020

Volltextzugriff (PDF)

Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients

Clinical and translational medicine, 2021-06, Vol.11 (6), p.e434-n/a

2021

Volltextzugriff (PDF)

Predicting Molecular Models: Where Are We Going?

EBioMedicine, 2015-11, Vol.2 (11), p.1594-1595

2015

Volltextzugriff (PDF)

Side effects of immunotherapy: a constant challenge for oncologists

Current opinion in oncology, 2019-07, Vol.31 (4), p.280

2019

Volltextzugriff (PDF)

Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger

Urologic oncology, 2015-06, Vol.33 (6), p.265.e15-265.e21

2015

Volltextzugriff (PDF)

Improved quality of life is the way to longer life

The lancet oncology, 2016-07, Vol.17 (7), p.862-863

2016

Volltextzugriff (PDF)

Combination therapies for patients with metastatic renal cell carcinoma

The lancet oncology, 2018-03, Vol.19 (3), p.281-283

2018

Volltextzugriff (PDF)

A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5052-5052

2023

Volltextzugriff (PDF)

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS262-TPS262

2020

Volltextzugriff (PDF)

Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib

Tumori, 2014-03, Vol.100 (2), p.e59-e62

2014

Volltextzugriff (PDF)

Case Report of a Long-surviving Man with Metastatic Renal Cell Carcinoma Treated with Pazopanib

Tumori, 2014-03, Vol.100 (2), p.59-62

2014

Volltextzugriff (PDF)

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Future oncology (London, England), 2021-09, Vol.17 (25), p.3291-3299

2021

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(77)
Buchkapitel
(1)

Sprache

Englisch
(78)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review

Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study

Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma

Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients

Predicting Molecular Models: Where Are We Going?

Side effects of immunotherapy: a constant challenge for oncologists

Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger

Improved quality of life is the way to longer life

Combination therapies for patients with metastatic renal cell carcinoma

A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921

Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib

Case Report of a Long-surviving Man with Metastatic Renal Cell Carcinoma Treated with Pazopanib

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Suchergebnisse filtern